Escalon Medical Corp. enters its Q3 2026 earnings on May 18 with one genuinely fresh development to chew on: LPL Financial quietly built a new 7.9% stake in the company, filed via Schedule 13G on April 9.
That institutional move is the standout for a stock this thinly traded. LPL reported holding 586,749 shares — a position built from zero — as of March 31. With a total market cap around $1.26 million, that's a meaningful slice of a micro-cap OTC name. The only other tracked institutional holder is the Estate of Richard J. DePiano Sr., which holds 1.9% and has been static. Combined, two institutions account for roughly 10% of shares, leaving a very thin publicly traded pool.
The short positioning picture is effectively empty. Short interest is negligible at well under 0.1% of the free float, and borrow availability is at maximum — the lending pool is wide open with no meaningful demand from the short side. Borrowing costs have also collapsed from double-digit levels seen in 2022 and 2023 to below 1%. The lending market, in short, holds no tension here.
The earnings backdrop is mixed. The most recent print, reported in February, showed Q2 revenues of $3.59 million — up about 11% year-on-year — but net income fell to $97,000 from $246,000 a year earlier. For the six-month period, the company swung to a net loss of $142,000, against net income of $214,000 in the prior-year half. The stock reacted sharply to that report, jumping roughly 16% on the day. An additional earnings event logged a 10% move the same week. The prior quarter, in November 2025, saw the stock fall about 9%. The pattern across recent prints has been volatile in both directions.
The stock has been flat on the week and the day, closing at $0.17 on April 28, though it has edged up roughly 6% over the past month. With FINRA reporting just 15 shares short in its most recent fortnightly count, there is no short-side catalyst in play. The factor scores flag a high utilization rank (92nd percentile) and short score rank (90th percentile), though both likely reflect the micro-cap, thin-float characteristics of the name rather than any active short thesis.
The next catalyst is the May 18 earnings date, where the question is whether the revenue growth trend from Q2 can offset the margin compression that turned a six-month profitable period into a loss.
See the live data behind this article on ORTEX.
Open ESMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
